reports
Kadimastem Ltd: 1 director
A director at Kadimastem Ltd sold 2,230,144 shares at 1.072ILS and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
DGAP-News: Kadimastem Receives US Patent For Amyotrophic Lateral Scler...
DGAP-News: Kadimastem Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment 09.08.2022 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company developing treatments for ALS and diabetes, has been granted a patent from the United States Patent and Trademark Office for its cell therapy technology for treating ALS and other neurodegenerative diseases. This US patent joins additional patents granted to Kadimastem in the US, Israel and Europe for the treatment of ALS an...
DGAP-News: Kadimastem and Implant Therapeutics, Inc. Sign an Evaluatio...
DGAP-News: Kadimastem Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells 08.06.2022 / 13:00 The issuer is solely responsible for the content of this announcement. If the feasibility study is successful, it would be a significant step forward towards pancreatic tissue engineering that could be used to develop Kadimastem’s IsletRx for diabetes in a way where transplantation would be possible without concern of immune rejection (TASE: KDST), a clinical stage cell therapy company developing a treatme...
DGAP-News: Kadimastem Awarded Patent in Japan for AstroRx® For ALS and...
DGAP-News: Kadimastem Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening 30.05.2022 / 15:10 The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, exploring one for multiple sclerosis and developing a potential cure for diabetes, has received a patent from the Japan Patent Office for ® for the treatment of ALS and drug screening. The patent also protects AstroRx® for the treatment of multiple sclerosis. AstroRx® is comprised of a differentiated cell...
DGAP-News: Kadimastem Expands R&D Program to Include Multiple Sclerosi...
DGAP-News: Kadimastem Kadimastem Expands R&D Program to Include Multiple Sclerosis 18.05.2022 / 13:00 The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). Kadimastem remains on track to submit IND to the FDA before the end of 2022 to begin a multicenter clinical trial of for ALS in 2023 in the U.S.As part of this initiative, the comp...
DGAP-News: Kadimastem Receives Grant for a Total Budget of NIS 10 Mill...
DGAP-News: Kadimastem Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) from the Israeli Innovation Authority 03.03.2022 / 14:05 The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company developing a treatment for and a potential cure for , has received a grant from the (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million). The grant will support the Company's FDA IND enabling studiesFor its next clinical trial in ALS patients...
DGAP-News: Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budg...
DGAP-News: Kadimastem Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority 13.12.2021 / 13:00 The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant of NIS 1.6 million ($500K), 40% of the approved budget of NIS 4 million ($1.29M) from the . This brings the total amount of financing raised by Kadimastem in 2021 to NIS 51.6 million ($16 M). As Kadimastem intends to submit the...
DGAP-News: Kadimastem Raises $5 million In Private Placement
DGAP-News: Kadimastem Kadimastem Raises $5 million In Private Placement 26.10.2021 / 07:49 The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company, announced today a NIS 16.1 million ($5 million) private placement, led by funds Clover Wolf Capital and Alpha Capital Anstalt and with the additional investment in the company by its controlling shareholders, Professor Michel Revel and Mr. Julien Ruggieri. In addition to the placement announced today, the investors were also given an option to purchase an addit...
DGAP-News: Kadimastem Raises NIS 16.1 million ($5 million) In Private ...
DGAP-News: Kadimastem Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement 25.10.2021 / 14:09 The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company, announced today a NIS 16.1 million ($5 million) private placement, led by funds Clover Wolf Capital and Alpha Capital Anstalt and with the additional investment in the company by its controlling shareholders, Professor Michel Revel and Mr. Julien Ruggieri. In addition to the placement announced today, the investors were also given an option t...
DGAP-News: Kadimastem Holds Successful Preliminary Meeting with the FD...
DGAP-News: Kadimastem Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes 12.10.2021 / 15:55 The issuer is solely responsible for the content of this announcement. (TASE: KDST), a clinical stage cell therapy company developing cell therapy treatments for ALS and diabetes, announced today that the Company held a preliminary meeting with the FDA (INTERACT) on October 7, 2021 regarding IsletRx, the company's cell therapy product in development for the treatment of diabetes. During the meeting, Kadimastem r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.